Global Blood Glucose Monitoring Market 2023-2029

February 2023 | 88 pages | ID: GE6ACF406659EN
Gen Consulting Company

Abstracts

About 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades. Blood glucose monitoring is an essential part of case management in clients with diabetes. This information can be used to guide decisions about a patient's diabetes care plan. Having the right care plan in place can help prevent or delay the onset of diabetes complications. According to the latest estimates, the global blood glucose monitoring market is set to achieve an incremental growth of USD 15.2 billion, accelerating at a CAGR of almost 9.2% during the forecast period 2023-2029.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global blood glucose monitoring market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, usage, distribution channel, end user, and region. The global market for blood glucose monitoring can be segmented by product: continuous glucose monitoring (CGM) devices, self monitoring blood glucose (SMBG) devices. SMBG held the highest share in the global blood glucose monitoring market. However, the CGM segment is forecast to register the highest CAGR during the forecast period 2023 - 2029. Blood glucose monitoring market is further segmented by usage: personal BGM, professional BGM. The personal BGM segment was the largest contributor to the global blood glucose monitoring market in 2022. Based on distribution channel, the blood glucose monitoring market is segmented into: offline, online. The offline segment is estimated to account for the largest share of the global blood glucose monitoring market. On the basis of end user, the blood glucose monitoring market also can be divided into: hospitals and clinics, individuals, others. Blood glucose monitoring market by region is categorized into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America.

The self monitoring blood glucose (SMBG) devices market is further segmented into glucometers, lancets, test strips. Among these, the test strips segment was accounted for the highest revenue generator in 2022. Furthermore, the continuous glucose monitoring (CGM) devices market has been categorized into durables, sensors. Among these, sensors segment occupied the largest market share in 2022. However, the durables segment is expected to display the highest CAGR during the forecast period.

Market Segmentation

By product: continuous glucose monitoring (CGM) devices, self monitoring blood glucose (SMBG) devices

By usage: personal BGM, professional BGM

By distribution channel: offline, online

By end user: hospitals and clinics, individuals, others

By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report also provides analysis of the key companies of the industry and their detailed company profiles including A. Menarini Diagnostics S.r.l., Abbott Laboratories, ACON Laboratories, Inc., AgaMatrix Inc., Alliance International Co., Ltd., Andon Health Co., Ltd., Arkray Inc., Ascensia Diabetes Care Holdings AG, B. Braun Holding GmbH & Co. KG, Beurer GmbH, Bionime Corporation, Bioptik Ltd., BioTelemetry, Inc. (Koninklijke Philips N.V.), BTNX Inc., DarioHealth Corp., Dexcom Inc., Die Medisana GmbH, EPS Bio Technology Corp/EasyMax, F. Hoffmann-La Roche AG, ForaCare Inc., GlySens Incorporated, Hannox International Corp., Insulet Corporation, Life Scan Inc., Medisana AG, Medtronic plc, Novo Nordisk A/S, Rossmax International Ltd., Senseonics Holdings, Inc., Ypsomed Holding AG, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report

• To analyze and forecast the market size of the global blood glucose monitoring market.
• To classify and forecast the global blood glucose monitoring market based on product, usage, distribution channel, end user, region.
• To identify drivers and challenges for the global blood glucose monitoring market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global blood glucose monitoring market.
• To identify and analyze the profile of leading players operating in the global blood glucose monitoring market.

Why Choose This Report

• Gain a reliable outlook of the global blood glucose monitoring market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY PRODUCT

Continuous glucose monitoring (CGM) devices
Self monitoring blood glucose (SMBG) devices

PART 6. MARKET BREAKDOWN BY USAGE

Personal BGM
Professional BGM

PART 7. MARKET BREAKDOWN BY DISTRIBUTION CHANNEL

Offline
Online

PART 8. MARKET BREAKDOWN BY END USER

Hospitals and clinics
Individuals
Others

PART 9. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 10. KEY COMPANIES

A. Menarini Diagnostics S.r.l.
Abbott Laboratories
ACON Laboratories, Inc.
AgaMatrix Inc.
Alliance International Co., Ltd.
Andon Health Co., Ltd.
Arkray Inc.
Ascensia Diabetes Care Holdings AG
B. Braun Holding GmbH & Co. KG
Beurer GmbH
Bionime Corporation
Bioptik Ltd.
BioTelemetry, Inc. (Koninklijke Philips N.V.)
BTNX Inc.
DarioHealth Corp.
Dexcom Inc.
Die Medisana GmbH
EPS Bio Technology Corp/EasyMax
F. Hoffmann-La Roche AG
ForaCare Inc.
GlySens Incorporated
Hannox International Corp.
Insulet Corporation
Life Scan Inc.
Medisana AG
Medtronic plc
Novo Nordisk A/S
Rossmax International Ltd.
Senseonics Holdings, Inc.
Ypsomed Holding AG
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER